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Abstract 
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 
2019 (COVID-19), is a threat to the global healthcare system and economic security. As of July 2020, no specific 
drugs or vaccines are yet available for COVID-19, fast and accurate diagnosis for SARS-CoV-2 is essential in 
slowing down the spread of COVID-19 and for efficient implementation of control and containment strategies. 
Magnetic immunoassay is a novel and emerging topic representing the frontiers of current biosensing and 
magnetics areas. The past decade has seen rapid growth in applying magnetic tools for biological and biomedical 
applications. Recent advances in magnetic materials and nanotechnologies have transformed current diagnostic 
methods to nanoscale and pushed the detection limit to early stage disease diagnosis. Herein, this review covers 
the literatures of magnetic immunoassay platforms for virus and pathogen detections, before COVID-19. We 
reviewed the popular magnetic immunoassay platforms including magnetoresistance (MR) sensors, magnetic 
particle spectroscopy (MPS), and nuclear magnetic resonance (NMR). Magnetic Point-of-Care (POC) diagnostic 
kits are also reviewed aiming at developing plug-and-play diagnostics to manage the SARS-CoV-2 outbreak as 
well as preventing future epidemics. In addition, other platforms that use magnetic materials as auxiliary tools for 
enhanced pathogen and virus detections are also covered. The goal of this review is to inform the researchers of 
diagnostic and surveillance platforms for SARS-CoV-2 and their performances.  
Keywords: SARS-CoV-2, COVID-19, virus, magnetic immunoassay, biosensor, magnetoresistance, magnetic 
particle spectroscopy, Nuclear Magnetic Resonance 
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1. Introduction 
In December 2019, a cluster of severe pneumonia cases of unknown cause was reported in Wuhan, Hubei province, 
China.[1] A novel strain of coronavirus belonging to the same family of viruses that cause severe acute respiratory 
syndrome (SARS) and Middle East respiratory syndrome (MERS) was subsequently isolated from 
bronchoalveolar lavage fluid (BALF).[2,3] The virus was initially named 2019 novel coronavirus (2019-nCoV) 
and later renamed as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).[4,5] The outbreak that 
began in China has rapidly expanded worldwide and on January 30, 2020 the World Health Organization (WHO) 
declared novel corona virus infection a Public Health Emergency of International Concern and the illness was 
named coronavirus disease 2019 (COVID-19). COVID-19 was declared as a pandemic by WHO on March 11, 
2020 due to its rapid spread in various countries around the world. SARS-CoV-2 is an enveloped, positive-strand 
RNA virus with large RNA genome of ~30kb with genome characteristics similar to known coronaviruses.[6,7] 
The coronavirus genomic RNA encodes replication and transcription complex from a single large open reading 
frame (ORF1ab) and structural proteins of the virus.[8] The major structural proteins of corona virus are spike 
(S), envelope (E), membrane (M), and nucleocapsid (N). 
    There is currently no medication to treat COVID-19. Since clinical manifestation of COVID-19 ranges from 
mild flu-like symptoms to life threatening pneumonia and acute respiratory illness, it is essential to have proper 
diagnosis during early stage of infection for efficient implementation of control measures to slow down the spread 
of COVID-19.[9–11] Currently, real time reverse transcription polymerase chain reaction (RT-PCR) is the most 
widely used laboratory test for diagnosis of COVID-19. RT-PCR detects SARS-CoV-2 RNA and target different 
genomic regions of viral RNA.[12–14] Although RT-PCR is sensitive technique, they require expensive 
laboratory equipment, trained technicians to perform the test, and can take up to 48 hours to generate results. In 
addition, studies have found up to 30% false negative rate for RT-PCR early in the course of infection.[15–18] 
Several laboratories around the world are working on improving RT-PCR methods and to develop alternative 
molecular diagnostic platforms. Isothermal nucleic acid amplification that allow rapid amplification of target 
sequences at a single constant temperature are employed in several tests including ID NOW COVID-19 test from 
Abbott diagnostics. ID NOW is a rapid, point-of-care test that allow direct detection of viral RNA from the clinical 
sample without the need for RNA extraction. However, recent studies have found false negative rates ranging 
from 12-48% mainly due to inappropriate condition of sample transportation and inappropriate sample.[19–21] 
Moreover, this can test only one sample per run. Serological methods like enzyme-linked immunosorbent assay 
(ELISA) and lateral flow immunochromatography test that detect antibodies can be used to monitor immunity to 
infection and disease progression.[22] Although negative SARS-CoV-2 antibody results does not rule out 
COVID-19, serological assays will help in assessing previous exposure to SARS-CoV-2 in a population and 
therefore have a potential use in understanding the epidemiology of COVID-19. Currently available serological 
assays can detect IgM, IgG, or IgA antibodies to spike (S) or nucleocapsid (N) protein.[23–25] However, potential 
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cross reactivity of SARS-CoV-2 antibodies with antibodies generated against other coronaviruses is a challenge 
in developing accurate serological test for COVID-19.[26] 
    Among other biosensing technologies, magnetic biosensors have attracted special attention in the past 20 years. 
Both surface-based and volume-based magnetic biosensors have been developed for the detection of viruses, 
pathogens, cancer biomarkers, metallic ions, etc.[27–36] In magnetic biosensors, the magnetic tags (usually 
magnetic nanoparticles (MNPs)) are functionalized with antibodies or DNA/RNA probes that can specifically 
bind to target analytes. The concentration of the target analytes is thus converted to the magnetic signals that are 
generated by these magnetic tags. Compared to optical, plasmonic, and electrochemical biosensors, magnetic 
biosensors exhibit low background noise since most of the biological environment is non-magnetic. The sensor 
signal is also less influenced by the types of the sample matrix, enabling accurate and reliable detection 
processes.[37] The number of published papers on magnetic biosensors is summarized in Figure 1, which 
indicates an increasing scientific interest on this topic. 
 
Figure 1. Number of publications on magnetic biosensors in the past 20 years as of July 8th, 2020. The data is 
acquired from Web of Science core collection with the keywords “magnetic biosensors” and “magnetic biological 
sensors”. 
 
Most magnetic biosensors fall into several categories, namely magnetoresistance (MR) sensors, magnetic 
particle spectroscopy (MPS) platforms, and nuclear magnetic resonance (NMR) platforms. MR sensors are 
surface-based technologies which are sensitive to the stray field from the MNPs bound to the proximity of the 
sensor surface. The MR-based magnetic immunoassays are reviewed in Section 2, this kind of assay scheme is 
achieved by converting the binding events of MNPs (due to the presence of target analytes) to readable electric 
signals. On the contrary, MPS platforms (reviewed in Section 3) directly detect the dynamic magnetic responses 
of MNPs and thus, MNPs are the only signal sources and indicators for probing target analytes from non-magnetic 
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mediums. NMR platforms (reviewed in Section 4) are using MNPs as contrast enhancers to introduce local 
magnetic field inhomogeneity and to disturb the precession frequency variations in millions of surrounding water 
protons. Thus, the high sensitivity NMR-based immunoassays intrinsically benefit from the MNP contrast agents. 
In addition, other immunoassay platforms that use magnetic materials as auxiliary tools to enhance the detection 
performances are also reviewed in Section 5. In this review, magnetic biosensors’ application in virus and 
pathogen detection will be summarized and discussed based on the different working principle of the technologies. 
 
2. Magnetoresistance (MR) Platforms 
2.1 Magnetoresistance (MR) 
Magnetoresistance (MR) was at first discovered by William Thompson who coined the term anisotropic 
magnetoresistance (AMR).[38] The physical observation of AMR shows that the resistivities of both Ni and Fe 
increase when the charge current is applied parallel to the magnetization and decrease when charge current is 
applied perpendicular to the magnetization.[39] This AMR effect originates from the spin orbit interactions and 
was experimentally and quantitatively demonstrated by Fert and Campbell.[40] However, the maximum 
resistance change recorded from AMR devices is only around 2 %, which renders it unsuitable for most 
applications. Regarding this, a detailed review of the AMR effect in thin films and bulk materials can be found in 
Ref. [39]. Herein, the AMR biosensors will not be discussed due to their limited applications in magnetic 
biosensing. 
Giant magnetoresistance (GMR) was at first observed from the Fe/Cr multilayers grown with molecular beam 
epitaxy (MBE) by Albert Fert and Peter Grunberg.[41,42] These multilayers exhibit a resistance change 
significantly higher than the AMR devices. The GMR effect primarily exists in multilayer structures with 
alternating ferromagnetic and non-magnetic metallic layers. When the magnetizations of two adjacent 
ferromagnetic layers are parallel, the multilayers show low resistance and when magnetizations are anti-parallel, 
multilayers exhibit a high-resistance state. The industrial breakthrough for GMR discovery was made when Parkin 
et al. observed the GMR effect from DC sputtered multilayer structures.[43] Although the GMR effect was 
primarily observed in a thin film or layered system (see Figure 2(A)), it is also observed in other systems such as 
Co-Au, Co-Ag and Fe-Ag granular films.[44–48] GMR effect in granular films (see Figure 2(B)) is highly related 
to the spin dependent interfacial scattering, inter-particle coupling, and several are significant for biosensing 
purposes because of their capability to adapt to the shapes of different biomolecules.[49,50] In comparison to 
other types of sensors, the ability of flexible GMR sensors to respond to external magnetic field makes them a 
perfect candidate for wearable real-time body activity monitoring and evaluating drug delivery effectiveness. As 
no experimental demonstration on flexible MR-based detection of viruses/pathogens has been reported, further 
discussion on flexible GMR-based bio-detection is restricted in the subsequent sections. 
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    Magnetic tunnel junctions (MTJs) have similar stack structure (see Figure 2(C)) to that of the GMR spin valves 
except that the adjacent ferromagnetic layers are separated by an insulating layer which is usually an oxide. In 
the earlier days, AlOx was used [51,52]. Later, this insulating layer was replaced by MgO material for smaller 
lattice mismatch and interface instability and thus, higher tunnel magnetoresistance (TMR) ratio [53,54]. The 
most important characteristic of a MTJ structure is its transfer curve as shown in Figure 2(D). In the transfer curve, 
two characteristics are of utmost importance: MR ratio and sensitivity. The physical characterization of the MR 
ratio is the rate of change in MR deice resistance along with varying magnetic field. Its sensitivity is measured by 
the slope of the transfer curve at an intensity of the magnetic field. In this regard, an interesting point to note is 
the tradeoff between the sensitivity and the linear magnetic field response range for MR sensors. A large linear 
response range in the transfer curve is attained with great ease in GMR sensors, although this comes with a 
compromise on the sensitivity. On the other hand, even though MTJ sensors possess high sensitivity, additional 
stack designs or supporting parts such as bias magnets are required to achieve high linearity.[55–57] Another 
factor which comes into play for all sensors in the nanoscale is the signal-to-noise ratio (SNR). Generally, MTJs 
show higher SNR than GMR sensors. However, the shot noise from the discontinuities in the conduction medium 
can cause the SNRs of MTJs to suffer.[58] With the advancing of thin film deposition and nanofabrication 
technologies, the TMR ratio has been increased dramatically during the past 20 years from ~20% to over 
200%.[53,59–61] 
 
Figure 2. (A) A typical GMR stack structure used for biosensing. (B) Magnetoresistance of Co-Ag matrix, the 
evidence of granular GMR. (C) A typical MTJ structure used for biosensing. (D) A typical transfer curve of a 
MR sensor. (A) reprinted with permission from [59], Copyright (2019) IOP Publishing. (B) reprinted with 
permission from [47], Copyright (2006) Elsevier. (C) reprinted from [60] under the terms of the Creative 
Commons Attribution License (CC BY). (D) reprinted from [61] under the terms and conditions of the Creative 
Commons Attribution (CC BY) license. 
 
2.2 Giant Magnetoresistance (GMR) Platform 
Since Baselt et al. reported the first GMR-based biosensor using the Bead Array Counter (BARC) microarray, 
GMR-based biosensing has been attracting increasing attentions amongst the community.[62] This section 
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reviews the GMR biosensors for detecting viruses and pathogens, and compares their limit of detections (LODs) 
and advantages over the existing biosensing tools. Take the sandwich immunoassay as an example (see Figure 
3(A)), where the capture antibodies specifically targeting on analytes (such as antigens from viruses/pathogens) 
are pre-functionalized on the GMR sensor surface. Then biofluid samples are added and specific antibody-antigen 
bindings take place on the sensor surface. Usually a wash step is added to remove the unbound analytes from 
sensing areas. Then the detection antibody functionalized MNPs are added to the GMR sensing areas, forming 
the MNP – detection antibody – antigen – capture antibody complexes. Thus, the amount of MNPs captured to 
the proximity of sensor surface is directly proportional to the number of antigens in the testing sample. 
Furthermore, this sandwich immunoassay scheme significantly enhances the detection specificity. To attain the 
best performance, superparamagnetic MNPs are prevalently used to avoid clustering and sedimentation to sensor 
surfaces. 
    Krishna et al. reported a GMR benchtop system for the detection of H1N1 strain of the influenza A virus (IAV) 
within a concentration range of 103 to 105 TCID50/mL.[63] Wu et al. reported a portable GMR biosensing device 
named Z-Lab (see Figure 3(B)) to detect IAV.[64] They achieved a LOD of 15 ng/mL for detecting H1N1 
nucleoprotein (see Figure 3(C)) and a LOD of 125 TCID50/mL for detecting purified H3N2 variant virus (H3N2v) 
from buffer solutions, with the overall assay time of less than 10 mins. Later, Su et al. reported the wash-free 
immunoassay scheme for detecting H1N1 and H3N2v from spiked nasal swab samples with a reported LOD of 
250 TCID50/mL.[27] This wash-free immunoassay approach allows for detections handled by non-technicians 
with minimum training requirements. Another group from Stanford University reported a similar GMR-based 
portable system for on-site bioassays (see Figure 3(D)). They reported the multiplexed assay of human 
immunoglobulin G and M (IgG and IgM) antibodies with sensitives down to 0.07 and 0.33 nanomolar, 
respectively. Figure 3(E) shows the real-time signals as measured by their portable device for detecting various 
concentrations of IgG over a 10 min measurement period.[65] Zhi et al. reported detection of Hepatitis B virus 
(HBV) using a GMR biochip integrated with microfluidic channel with a detection sensitivity of 200 IU/mL for 
HBV DNA molecules.[66] In their work, the integration of a microfluidic channel increased the ease of handling 
smaller sample volumes on the sensing area. A good follow-up of this work with significantly improved LOD 
down to 10 copies of target HBV DNA molecules has been reported.[67] GMR platforms have also been reported 
for bacteria detections. For instance, Sun et al. reported the detection of Escherichia coli O157H:H7 antigen using 
the GMR biosensing scheme with a reported LOD of 100 colony forming unit (CFU)/mL.[68] Gupta et al. 
reported the detection of Mycobacterium tuberculosis specific antigen - ESAT-6 using the GMR scheme and 
reported a LOD of 1 pM.[69] 
    The key take-away point here is that several experimental demonstrations of the magnetic assays for virus 
detection based on GMRs and the reported LOD indicate that GMR-based bioassay is one of the promising 
candidates for onsite, rapid, and sensitive detection of COVID-19. 
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Figure 3. (A) The sandwich bioassay mechanism of a GMR biosensor forming capture antibody - target antigen 
- detection antibody - MNP complex. (B) Photograph of the GMR-based handheld device reported by researchers 
from University of Minnesota. (C) The response curves of H1N1 nucleoprotein as detected by the handheld device 
in (B) showing a LOD of 15 ng/mL. (D) Photograph of another GMR-based portable device reported by the 
researchers from Stanford University. (E) The response curves of IgG antibodies detected by device shown in (D) 
depicting a LOD of 10 ng/mL. (A) reprinted from [63] under the terms of the Creative Commons Attribution 
License (CC BY). (B) & (C) reprinted from [64], Copyright (2017) American Chemical Society. (D) & (E) 
reprinted from [65], Copyright (2016) Elsevier. 
 
2.3 Magnetic Tunnel Junction (MTJ) Platform 
The first ever proof-of-concept MTJ as biosensor was reported by Grancharov et al. in 2005.[70] They 
demonstrated a unique method for antigen and DNA detection at room temperature using monodispersed 
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manganese ferrite nanoparticles as the magnetic tags. Since then, there have been several attempts to employ 
MTJs as biosensors.[61,71–73] However, most of their attempts were limited to genotyping applications of TMR 
sensors. In the year of 2017, Sharma et al. demonstrated a Poly(methyl methacrylate) (PMMA) microfluidic 
integrated MTJ platform (see Figure 4 (A) & (B)) for detecting pathogenic DNA from Hepatitis E virus (HEV), 
Listeria monocytogenes, and Salmonella typhimurium bacteria.[74] Figure 4(C) & (D) shows the normalized 
signal acquires as a function of time from MTJ sensors functionalized with HEV and Listeria target DNA probes, 
respectively, with an assay time of around 100 min. The excellent sensitivity and specificity of the microfluidic 
integrated MTJ platform could pave the way for lab-on-chip multiplexed apparatus and the point-of-care (POC) 
detection of pathogenic antigens. Very recently, Li et al. experimentally demonstrated the detection of HIV-1 
antigen p24 by MTJ sensors with an assay time of less than 10 mins and a LOD in the orders of 0.01 µg/mL.[75]  
    With improved circuitry design and the ease of nanofabrication, there is a trend to use MTJ sensors for 
immunoassays. Gervasoni et al. used a 12-channel dual lock-in platform to improve the circuitry for the signal 
generation and acquisition in their MTJ sensing system (see Figure 4(E))[73] By customizing the differential 
amplifier, low-noise voltage references, and detailed analysis of temperature fluctuation within the system, they 
achieved a sub-ppm resolution of the lock-in amplifier and an order of magnitude better than commercial state-
of-the-art instrument. However, there are several disadvantages of MTJs as biosensors compared to GMR sensors. 
The requirement for top electrodes increases the distance between the MNPs bound to the surface and the free 
layer of the MTJ sensor. As the stray fields of the MNPs decay rapidly with the increase of the distance, the 
sensitivity of the MTJ sensors is often sacrificed despite their high TMR ratio. Furthermore, the difficulty to 
achieve high linearity and low coercivity also remains a challenge for MTJs. More dedicate design of the stack 
structure and the fabrication process are needed to take full advantage of the high signal level induced by the large 
TMR ratio. 
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Figure 4. (A) SEM image of the sensor array comprising 12 MTJs with a common ground contact. (B) Photograph 
of the microfluidic channel integrated with the MTJ biosensors to facilitate handling of extremely small sample 
volumes. (C) & (D) are the normalized MTJ signals acquired as a function of time from sensors functionalized 
with (C) HEV DNA probes for detecting 100 nM HEV target DNA and (D) Listeria DNA probes for detecting 
500 nM Listeria target DNA, respectively. Top panels show the photographs of sensor areas after magnetic bead 
immobilization. (E) The circuit schematic of the MTJ-based detection platform that mainly consists of two 
separate sinusoidal generators (DACs and amplifiers) and the readout circuit for 12 MTJ sensors (MUX, INA and 
ADC). Both the generation and processing of the input and acquired signals are performed on the FPGA. (A) - 
(D) reprinted with permission from [74], Copyright (2017) Elsevier. (E) reprinted with permission from [73], 
Copyright (2014) IEEE. 
 
Table 1. Comparison of Different Magnetic Immunoassay Platforms 
Platform Assay Time Pathogens Limit of Detection (LOD) Evaluated Matrices Ref. 
GMR 
< 10 mins 
H1N1 15 ng/mL for H1N1 nucleoprotein 
PBS* [64] 
H3N2v 125 TCID50/mL 
< 10 mins 
H1N1 250 TCID50/mL 
Nasal swab [63] 
H3N2v 250 TCID50/mL 
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15 mins HBV 200 IU/mL DNA Serum [66] 
N.A. E. coli O157H:H7 100 CFU/mL antigen in 1 mL sample PBS [68] 
N.A. 
Mycobacterium 
tuberculosis 
1 pM ESAT-6 protein N.A. [69] 
MTJ 
100 min 
HEV  N.A. 
PBS [74] 
Listeria N.A. 
N.A. HIV 0.01 µg/mL antigen p24 N.A. [75] 
MPS 
30 min Clostridium botulinum 
0.22, 0.11, and 0.32 ng/mL for BoNT-A, -B, 
and -E, respectively 
Milk, apple, and 
orange juices 
[76] 
25 min 
Staphylococcus aureus 
4 and 10 pg/mL for TSST and SEA 
Milk [77] 
2 h 0.1 and 0.3 ng/mL for TSST and SEA 
10 s H1N1 4.4 pmole for H1N1 nucleoprotein PBS [78] 
42 min SARS-CoV-2 
2.96 ng/mL for SARS-CoV-2 anti-spike-
protein antibodies  
PBS 
[79] 
3.36 ng/mL SARS-CoV-2 anti-spike-protein 
antibodies 
Serum 
NMR 
1 min E. coli O157:H7 
76 CFU/mL Water  
[80] 
92 CFU/mL Milk 
2.5 h 
Mycobacterium 
tuberculosis 
1 nM ssDNA in 1 μL sample Sputum [81] 
*PBS: Phosphate buffer saline 
 
3. Magnetic Particle Spectroscopy (MPS) Platforms 
3.1 Magnetic Particle Spectroscopy (MPS) 
Magnetic particle spectroscopy (MPS) is firstly reported by Krause et al. and Nikitin et al. in 2006.[82,83] It is a 
derivative technology from magnetic particle imaging (MPI) where the tomographic images can be reconstructed 
by exploiting the nonlinear magnetic responses of MNPs.[84,85] Herein, in MPS-based immunoassays, the 
nonlinear magnetic responses of MNPs along with their rotational degree of freedom are used as metrics for 
different biosensing purposes. In a MPS platform, external sinusoidal magnetic fields (also called excitation fields) 
are applied to periodically magnetize (and magnetically saturate) the MNPs, as shown in Figure 5(A1 & A3).[76–
78,86–90] The time-varying dipolar magnetic fields generated by MNPs as a response to the applied fields (see 
Figure 5(A2 & A4)) are monitored by pick-up coils. As a result of Faraday’s law of induction, the time-varying 
electric voltage from pick-up coils are recorded and magnetic particle spectra are extracted for analysis, as shown 
in Figure 5(A3 & A6). Nowadays, there are two excitation field modes of MPS platforms that have been 
frequently reported: the mono-frequency and dual-frequency modes. In a mono-frequency MPS platform, one 
sinusoidal magnetic field with frequency f is applied and higher odd harmonics at 3f (the 3rd harmonic), 5f (the 
5th harmonic), 7f (the 7th harmonic), … are observed due to the nonlinear magnetic responses of MNPs.[86,87,91] 
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On the other hand, in a dual-frequency MPS platform, two sinusoidal magnetic fields with frequencies fH and fL 
are applied. The low frequency field fL periodically magnetizes MNPs while the high frequency field fH modulates 
these higher odd harmonics to high frequency range. Thus, higher odd harmonics at fH ±2fL (the 3rd harmonics), 
fH ±4fL (the 5th harmonics), fH ±6fL (the 7th harmonics), … are observed.[88,90,92–95] Although different in 
excitation modes, the detection mechanisms of periodically magnetize the MNPs and the extraction of higher odd 
harmonics as a result of nonlinear magnetic responses are identical.  
 
Figure 5. (A) Nonlinear magnetic responses of MNPs. (A1-A3) and (A4-A6) are the mono- and dual-frequency 
modes. A1 & A4 are the time domain excitation fields. A2 & A5 are the time domain magnetic responses. A3 & 
A6 are the magnetic particle spectra extracted from the pick-up coils. (B) Schematic drawing of the volume-based 
MPS immunoassay. (C) Schematic drawing of the surface-based MPS immunoassay. 
 
In addition, there are two types of MPS-based immunoassay platforms: the volume- and surface-based 
platforms (see Figure 5(B&C)). Although both platforms use dynamic magnetic responses of MNPs for 
characterizations, the degrees of freedom are different. In volume-based MPS platform, MNPs are dispersed in 
liquid phase. Upon the application of external magnetic fields, their magnetic moments relax to align to the 
external fields through the joint Brownian and Néel relaxation processes. Where Brownian relaxation is the 
physical rotation of whole MNP with its fixed magnetic moment and Néel relaxation is the rotation of the 
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magnetic moment inside a stational MNP. For volume-based MPS platforms, single-core, superparamagnetic 
nanoparticles (SPMNPs) that realign magnetic moments to external fields through a Brownian relaxation-
dominated process are favored. The Brownian relaxation process is affected by liquid viscosity, hydrodynamic 
volume of MNP, and temperature (note: other factors such as magnetic field amplitude, dipolar interactions 
between neighboring MNPs, magnetic properties of MNPs such as saturation magnetization, anisotropy, etc. are 
not in the scope of this review).[94–100] By surface functioning MNPs with biological/chemical reagents such 
as antibodies, DNA, RNA, proteins, the MNPs serve as high specificity probes to capture target analytes from 
biofluid samples. As shown in Figure 5(B), the successful recognition and binding events on MNPs cause 
increased hydrodynamic volume. Thus, Brownian relaxation is blocked, and magnetic responses are weakened. 
Larger phase lags between magnetic moments and the external fields are detected and lower harmonic amplitudes 
are observed from the magnetic particle spectra. In this volume-based MPS platform, the immunoassay is 
achieved by monitoring the reduced rotational freedom of MNPs in the testing suspension. On the other hand, in 
surface-based MPS platform, surface functionalized MNPs are captured to a solid substrate (i.e., reaction surface) 
and their Brownian rotational freedom are blocked, as shown in Figure 5(C). As a result, immunoassays are 
achieved by “counting” the number of MNPs captured to the solid substrate. In this section, different MPS 
platforms for virus and pathogen detections are reviewed and comparisons are made in Table 1. 
 
3.2 Surface-based MPS Platform 
Orlov et al. reported a multiplexed lateral flow (LF) assay for on-site detection of botulinum neurotoxin (BoNT) 
types A, B, and E from complex matrixes.[76] The BoNT-A, -B, and -E are proteins produced by anaerobic 
bacteria of Clostridium botulinum widely present in soil and water. In their work, the multiplexing is realized by 
combing MPS platform with LF measurement. LF method is based on various optical labels such as latex, gold, 
silver, and quantum dots, this method alone is difficult to achieve high sensitivity, quantitative immunoassays, 
especially in opaque mediums.[101–105] By replacing these optical labels with magnetic labels (i.e., MNPs), a 
potentially high sensitivity, high stability and low background noise (regardless of the optical transparency of 
biological media) biosensing platform is achieved. Herein, the authors combined three single-plex test strips with 
dissimilar positions of the test lines in a miniature cartridge. Each test strip is named A-strip, B-strip, and E-strip, 
respectively, for intended detection of BoNT-A, B, and E, respectively, as shown in Figure 6(D). Each strip is 
composed of overlapping sample pad, conjugation pad, nitrocellulose, and wicking pad on an adhesive plastic 
backing sheet, as show in Figure 6(A). The anti-BoNT capture antibodies (labeled as capture Ab in the figure) 
are deposited onto the nitrocellulose membrane as labeled test line. The corresponding MNP-detection antibody 
complexes (labeled as MP-Ab in the figure) are deposited on the conjugation pad. During an assay process, testing 
sample is deposited onto the sample pad and the fluid migrates along the test strip under the capillary action. The 
target analytes bind to MP-Ab and capture Ab on the test line. As shown in Figure 6(B), the distributions of MNPs 
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along the test strip exhibit three peaks corresponding to: remaining MNPs left in conjugation pad, MNPs bind on 
test line due to the presence of target analytes, unbounded MNPs collected at the wicking pad. The magnetic 
signal amplitudes recorded by MPS (labeled as MPQ reader in the figure) are positively correlated with the 
concentration (quantity) of target analytes. The specifically captured MNPs on the test line of the nitrocellulose 
membrane can be seen in the scanning electron microscope (SEM) image shown in Figure 6(C). The multiplexed 
assay procedures and measuring setup are like the single-plex assay, by replacing the single-plex strip with a 
cartridge. Sample is deposited on the front end of cartridge and after ~25 min the cartridge is inserted into the 
MPQ reader for measurements. Using this method, the authors have successfully and simultaneously detected 
three botulinum toxin serotypes from complex liquid food matrixes such as whole milk and juices. 
 
Figure 6. (A) Test strip design based on sandwich-lateral flow assay with antibody-conjugated MNPs as labels. 
(B) Typical distributions of MNPs along the lateral flow test strip for different concentrations of BoNT-A. (C) 
SEM image of MNPs specifically captured at the test line on the membrane. (D) Multiplexed assay setup: several 
single-plex test strips with dissimilar positions of the test lines are combined in a miniature cartridge. The cartridge 
with a sample deposited onto its front end is inserted into the portable magnetic particle quantification (MPQ) 
reader (i.e., MPS). Figure reprinted with permission from [76], Copyright (2016) American Chemical Society. 
 
    The authors successfully combined MPS method with lateral flow method. By conjugating different capture 
antibodies onto different locations of a test strip, a multiplexed assay platform is achieved. By replacing the optical 
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labels with MNPs, the measurements can analyze media regardless of the optical properties, offering sensitivity 
on the level of lab-based quantitative methods. 
Orlov et al. reported the application of MPS platform for detection of toxins produced by Staphylococcus 
aureus.[77] Due to the high stability and increasing resistance to antibacterial medications of these bacteria, the 
toxins are widely present in the environment and are frequently responsible for diverse fatal illnesses such as 
severe gastrointestinal diseases and toxic shock. In their work, they introduced a novel magnetic immunoassay 
on 3D fiber solid phase (see Figure 7(D)) that fits into a standard automatic pipet tip, as shown in Figure 7(A). 
The 3D porous filter surfaces are immobilized with capture antibodies specific to a definite toxin. These as-
prepared solid-phase filter immobilized with antibodies can be either used immediately or stored for a long time 
without compromising the properties. Two measurement formats are proposed: one for analysis of small volume 
samples (Figure 7(B), labeled as express MIA) and the other for large volume samples (Figure 7(C), labeled as 
high-volume MIA). In the express MIA, samples are dispensed simultaneously through all the tips by an electronic 
pipet. In the high-volume MIA, testing sample is pumped through the 3D fiber filters and the sample volume is 
determined by the pumping rate and time. In this step, the target analytes flowing through 3D porous filters are 
captured by the capture antibodies from the solid-phase filter. Further steps are the same for both formats. After 
passing the samples through the filters, each filter is washed to removed unbound reagents. Then 7-min dispensing 
of detection antibody-MNP complexes are carried out followed by another cycle of washing step. The MNPs that 
bound to the immunocomplex on the 3D porous fiber surfaces serve as labels to be recorded by the MPS reader. 
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Figure 7. (A) Schematic drawing of 3D porous filters as a solid phase immunoassay substrate in a cylinder. (B) 
& (C) are the schematic drawing of sandwich structure magnetic immunoassay on 3D fiber filters. 1, filter surface; 
2, capture antibody; 3, antigen; 4, biotinylated detection antibody; 5, streptavidin; 6, MNP. (A) Express MIA 
setup and (B) high volume MIA setup. (D) SEM surface morphology of cylindrical 3D fiber filters. Left, 
magnified lateral surface fragment (500× magnification); center, overview of lateral surface of the filter (60× 
magnification); right, top surface fragment (500× magnification). Figure reprinted with permission from [77], 
Copyright (2012) American Chemical Society. 
 
In June 2020, Pietschmann et al. reported the portable MPS surface-based immunoassay platform, MInD 
(Magnetic Immuno-Detection) for the detection of SARS-CoV-2 specific antibodies.[79] In their work, a porous 
polyethylene filter matrix coated with SARS-CoV-2 spike protein peptide is serving as the reaction surface (called 
immunofiltration columns in the paper). Varying concentrations of SARS-CoV-2 anti-spike-protein antibodies in 
PBS and human serum samples are spiked through the surface, followed by a wash step to remove unbound 
antibodies. Then biotinylated secondary antibodies are added and followed by another wash step. Finally, 
streptavidin-coated MNPs are added to the reaction surface, forming a [SARS-CoV-2 spike protein peptide] – 
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[SARS-CoV-2 anti-spike-protein antibody] – [secondary antibody] – [MNP] structure. After a final wash step, 
the MPS spectra of captured MNPs are measured. They achieved LODs of 2.96 ng/mL and 3.36 ng/mL for 
detecting SARS-CoV-2 anti-spike-protein antibodies from PBS and human serum, respectively. It shows better 
sensitivity and wider detection range than commonly used analytical biochemistry assay ELISA (enzyme-linked 
immunosorbent assay). However, negative control groups are PBS and serum without anti-spike-protein 
antibodies. The detection of antibodies generated in response to the infection can provide a larger window of time 
for indirectly detecting SARS-CoV-2. Antibody testing is very useful for the surveillance of COVID-19. One 
potential challenge of developing accurate antibody detections is the potential cross-reactivity of SARS-CoV-2 
antibodies with antibodies generated against other coronaviruses.[26] Yet in this work, the cross-reactivity with 
another coronavirus such as MERS coronavirus (MERS-CoV) and SARS coronavirus (SARS-CoV) are not tested. 
This point-of-care (POC) testing device allows for identifying people with immunity against SARS-CoV-2. 
 
3.3 Volume-based MPS Platform 
Wu et al. reported the volume-based MPS immunoassay platform utilizing the polyclonal antibodies induced 
cross-linking of MNPs for one-step, wash-free detection of H1N1 nucleoprotein molecules.[78] In their work, the 
MNPs are anchored with polyclonal IgG antibodies specific to H1N1 nucleoprotein. The H1N1 nucleoprotein 
molecule hosts multiple epitopes that serve as binding sites for IgG polyclonal antibodies. Thus, each 
nucleoprotein can bind to more than one MNPs, consequently assembling into MNP clusters. As shown in Figure 
8(A), seven experimental groups and two negative groups are prepared. For negative control 2 (sample index IX), 
magnetic responses of bare MNPs are recorded in the MPS platform. For negative control 1 (sample index VIII), 
the magnetic responses of polyclonal antibody-MNP complexes are recorded. For experimental groups I – VII, 
different concentrations of H1N1 nucleoprotein are mixed with polyclonal antibody-MNP complexes, the 
concentrations from highest to lowest are 4.42 μM (I), 2.21 μM (II), 884 nM (III), 442 nM (IV), 221 nM (V), 88 
nM (VI), and 44 nM (VII). Due to the varying abundancies of target analytes (i.e., H1N1 nucleoprotein), different 
degrees of MNP clustering are observed from samples I - VII. As shown in Figure 8(B), with the increasing 
degree of MNP clustering, the averaged MNP hydrodynamic size increases and the harmonic amplitude decreases. 
Figure 8(C) shows the 3rd and the 5th harmonic amplitudes from samples IX, VIII, and I. With the anchoring of 
polyclonal antibodies onto MNPs, a small decrease in harmonic amplitude is observed from sample VIII 
compared to sample IX. Which proves the successful conjugation of antibodies on MNPs and as a result, the 
hydrodynamic size slightly increases. The experimental group (sample I) shows substantial decrease in harmonic 
amplitudes due to the H1N1 nucleoprotein induced MNP clustering. As a side note, the harmonic ratios are also 
used as MNP-quantity independent factor for MPS-based immunoassays. Figure 8(D: [a] – [e]) shows the 
hydrodynamic size distributions of MNPs from samples II (2.21 μM), IV (442 nM), VI (88 nM), VIII (MNP-
antibody complex), and IX (bare MNP) measured by dynamic light scatter (DLS). The hydrodynamic size 
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increases after the anchoring of antibodies onto MNPs, then further increases in the presence of H1N1 
nucleoprotein. Figure 8(D: [f]) gives a more intuitive comparison between samples II (2.21 μM) and VIII (MNP-
antibody complex). The H1N1 nucleoprotein causes noticeable size peak shift from 46 nm to 59 nm. In addition, 
the bump between 200 nm and 300 nm indicates the presence of MNP clusters. In Figure WK4(E) & (F), the 
harmonic amplitudes recorded from samples I-IX show the similar trends. 
    This one-step, wash-free, volume-based MPS detection scheme allows for immunoassays on minimally 
processed biological samples and handled by non-technicians with minimum training requirements. Since the 
magnetic signals come for the whole volume of MNP suspension thus, removing the unbound MNPs from the 
sample could ensure higher detection sensitivity for this type of volume-based assay mode. 
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Figure 8. (A) Sample preparation flowcharts of the experimental and negative control groups. Nine MNP samples 
are prepared: sample indexes I−VII are MNP-antibody complexes in the presence of different concentrations of 
the H1N1 nucleoprotein; sample index VIII is an MNP-antibody complex in the absence of the H1N1 
nucleoprotein (denoted as “0 nM (MNP+Aby)”); sample index IX is bare MNP suspension (denoted as “Bare 
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MNP”). (B) The 3rd and the 5th harmonics along varying driving field frequencies (only samples I, VIII, and IX 
are plotted) collected by the MPS system. Boxplots of the harmonic ratios (R35) collected from samples I, VIII, 
and IX. (D) Statistical distribution of the hydrodynamic sizes of samples [a] II, [b] IV, [c] VI, [d] VIII, and [e] IX 
as characterized by DLS. [f] Comparison of the measured DLS size distribution curves between samples II (2.21 
μM) and VIII (0 nM, MNP+Aby). (E) and (F) are MPS measurements of the 3rd and the 5th harmonics from 
samples I−IX at varying driving field frequencies from 400 Hz to 20 kHz. Figure reprinted with permission from 
[78], Copyright (2020) American Chemical Society. 
 
4. Nuclear Magnetic Resonance (NMR) Platforms 
4.1 Nuclear Magnetic Resonance (NMR) 
Nuclear magnetic resonance (NMR) detects the MNP-labeled targets by measuring the precessional signal of 1H 
proton from the whole sample volume. In this way, the NMR platform is categorized as one type of volume-based 
immunoassay methods. Note: NMR-based immunoassay platform is also called magnetic relaxation switching 
(MRS). As shown in Figure 9(A), due to the high surface-to-volume ratio of MNPs, the local magnetic field 
inhomogeneity caused by MNP disturbs the precession frequency variations in millions of surrounding water 
protons, which accelerates the decay of the spin system’s phase coherence. In addition, the NMR-based detection 
intrinsically benefits from signal amplification and is able to achieve high detection sensitivity. As the mono 
dispersed MNPs aggregates upon binding to targets, the self-assembled clusters become more efficient in 
dephasing the nuclear spins of surrounding water protons, resulting in decreased T2 relaxation time. The reverse 
is also true upon the cluster disassembly. Figure 9(B) shows the steps of NMR-based immunoassay with MNP-
pathogen interaction, magnetic separation, and filtration. As is mentioned in Section 3.3, for volume-based 
biosensing platforms, the filtration step could effectively reduce the interference of unbound MNPs. The magnetic 
separation and filtration are not necessary but favored for high sensitivity immunoassays. 
    Issadore et al. reported a miniaturized NMR platform for point-of-care (POC) diagnostics.[106] A photograph 
and the schematic of the portable NMR platform are shown in Figure 9(C) & (D). The portable magnet, microcoil, 
and RF (radio frequency) matching circuit are packaged into a thermally insulating PMMA (poly- 
methylmethacrylate) housing. The custom electronics provides the NMR pulse sequences, collects the NMR 
signal, and communicates with external terminals. Samples are loaded into thin-wall polyimide tubes and 
introduced into the coil bore for NMR measurements. The modular coils can be plugged into the system to 
optimally accommodate sample volumes from 1 mL to 100 mL. This portable NMR platform with automatic 
measurement setting tuning provides users with easy-to-use interface and offers sensitive on-site diagnosis. With 
these capabilities, it is expected that NMR handheld device can be an essential tool for personal care and accurate 
diagnostics for infectious diseases in resource-limited areas, mitigating the burden in public health. 
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Figure 9. (A) The MNP induced spatial and temporal disturbance in the homogeneity and strength of the local 
magnetic field. (B) Schematic drawing of the working principle of the NMR based biosensor for pathogen 
detection. A filtration step is included in this scheme, thus, the interference of unbound MNPs can be effectively 
reduced, and MNPs in the eluted solution are proportional to the pathogen concentration. (D) Photograph of a 
portable NMR device. This system has a capacity for automatic system tuning and features a user-friendly 
interface. (D) Magnet assembly and the NMR probe design. The microcoil is embedded in a polydimethylsiloxane 
(PDMS) substrate. The entire coil bore is accessible by a sample, which maximizes the sample-filling factor. A 
thin-walled tube is used for sample loading. (A) & (B) are reprinted from [80] under the terms of the Creative 
Commons Attribution 4.0 International License. (C) & (D) are reprinted with permission from [106], Copyright 
(2011) The Royal Society of Chemistry. 
 
4.2 NMR-based Immunoassays 
Recent advances in micro- and nanofabrication has accelerated the development of portable NMR devices. Luo 
et al. reported the detection of foodborne bacteria Escherichia coli O157:H7 from drinking water and milk 
samples using a portable NMR platform.[80] The NMR system is able to generate 0.47 T of magnetic field and a 
high-power pulsed RF transmitter with ultra-low noise sensing circuitry capable of detecting weak NMR signal 
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at 0.1 μV. In their work, the bacteria are labeled with MNPs through the antibody-pathogen interactions. A 20 – 
30 min filtration step is carried out and followed by 1 min of NMR signal collection.  
    Liong et al. reported the detection of nucleic acids based on a magnetic barcoding strategy.[81] Where the 
PCR-amplified mycobacterial genes are sequence-specifically captured on microspheres, labeled by MNPs, and 
detected by NMR. All the components and steps are integrated into a single, small fluidic cartridge for streamlined 
on-chip assays. As shown in Figure 10(A), the sputum samples are first processed off-chip to extract DNA from 
mycobacterium tuberculosis and followed by PCR amplification. The amplicons are captured by polymeric beads 
modified with complementary capture DNA strands. Then MNPs modified with probed DNA strands bind to the 
opposite end of the amplicon. This capture DNA – target DNA – probe DNA scheme enhances the detection 
specificity and offers fast binding kinetics. After the removal of unbound MNPs, samples are subjected to NMR 
measurements. The MNPs captured due to target DNA cause faster relaxation of the 1H NMR signal and the 
decay rate is proportional of the MNP amount (and the amount of initial DNA), enabling the quantification of 
target DNA strands. The microfluid device for on-chip NMR measurements is shown in Figure 10(B). MNPs and 
buffers are preloaded in gated chambers, after the target DNA strands are PCR-amplified, the amplicons are 
combined with capture beads. The bead-DNA complexes are then mixed with MNPs and introduced into the 
mixing channel. The MNP labeled beads are filtered by an in-line membrane shown in Figure 10(C) and 
concentrated into the NMR chamber for measurements. 
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Figure 10. (A). Assay procedure. (B) Fluidic cartridge integrating PCR chambers, mixing channel, and a microcoil 
for NMR measurements. The entire cartridge is disposable to prevent cross-contamination of PCR-amplified 
products. (C) SEM image of the bead captured by the membrane filter, scale bar, 1 μm. The inset SEM image 
shows that the beads are efficiently labelled with MNPs, scale bar, 30 nm. Figure reprinted with permission from 
[81], Copyright (2013) Macmillan Publishers Limited. 
 
In addition to the immunoassay applications, saturation transfer difference (STD) NMR has emerged as a robust 
tool for characterizing protein binding and ligand screening.[107] It is used for identifying the underlying 
mechanisms of Hepatitis B virus X protein (HBx)-mediated carcinogenesis. Yue et al. used NMR-based 
metabolomics approach to systematically investigate the effects of HBx on cell metabolism.[108] Kusunoki et al. 
used NMR to characterize the interactions between the HBx BH3-like motif and Bcl-XL and showed that this 
motif binds to the common BH3-binding hydrophobic groove of Bcl-XL with a binding affinity of 89 μM.[109] 
NMR is applied for assessing the ability of an artificially designed oligopeptide in binding to Ebola virus Viral 
Protein 24 (VP24).[110] The successful protein-protein binding could inhibit the Ebola virus VP24 protein’s 
interaction with the human protein Karyopherin, thus, reduce the Ebola virus virulence. Vasile et al. used NMR 
to study the interactions between the sialic acid and influenza hemagglutinin (HA) from human and avian 
strains.[111] By screening the HA ligand-protein interactions, it could yield useful information for an efficient 
drug design. 
Herein, we have reviewed different magnetic immunoassay platforms and included the most representative 
literatures. The advantages and disadvantages of each platform are listed and compared in Table 2. 
 
Table 2. Advantages and Disadvantages of Different Magnetic Immunoassay Platforms 
Platforms Advantages Disadvantages 
GMR 
 High sensitivity. 
 Portable device available. 
 Mass production capability 
 Requires multiple wash steps thus, well trained technicians are 
needed. 
 Time consuming. 
 High cost per test, nanofabrication of GMR biosensors is 
required. 
MTJ 
 High sensitivity. 
 Mass production capability 
 Requires multiple wash steps thus, well trained technicians are 
needed. 
 High noise. Large distance from MNP to sensor surface. 
 Hard to acquire linear response. 
 Complicated fabrication process.  
 Time consuming. 
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 High cost per test, nanofabrication of MTJ biosensors is 
required. 
MPS, 
surface-based 
 High sensitivity. 
 Low cost per test. 
 Portable device available. 
 Requires multiple wash steps thus, well trained technicians are 
needed. 
 Time consuming. 
MPS, 
volume-based 
 Allows one-step wash-free 
detection. 
 Immunoassays can be 
handheld by non-technicians. 
 Low cost per test. 
 Portable device available. 
 Requires multiple wash steps thus, well trained technicians are 
needed. 
 Medium sensitivity 
 
NMR 
 High sensitivity. 
 Portable device available. 
 Requires multiple wash steps thus, well trained technicians are 
needed. 
 Time consuming. 
 
5. Other Magnetic Immunoassay Methods 
In most magnetic immunoassay platforms, MNPs are used as labels (e.g., MR sensors and MPS platforms) or 
contrast enhancers (e.g., NMR platforms) due to the unique magnetic properties, large surface-to-volume ratio, 
good stability and biocompatibility, and the facile surface functionalization with a great variety of reagents. In 
addition to the above technologies, other platforms that utilize MNPs as auxiliary tools for virus and pathogen 
detections have also been extensively reported. In this section, we reviewed some representative works that use 
magnetic materials are auxiliary tools for high sensitivity virus and pathogen detections, as summarized in Table 
3. 
    Chou et al. use surface functionalized MNPs as probes for efficient magnetic separation to achieve rapid and 
sensitive virus screening.[112] In their work, MNPs are functionalized with H5N2 viral antibodies targeting the 
hemagglutinin (HA) protein and capped with methoxy-terminated ethylene glycol to block nonspecific binding. 
Combined with magnetic separation, these MNPs show effective isolation of H5N2 from lysate for direct matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) readout without any 
elution steps. A limit of detection in the range of 104.5 – 105.5 TCID50 is achieved within a diagnosis time of one 
hour. The functionalized MNP probes can unambiguously differentiate the H5N2 viruses from other closely 
related subtypes such as H5N1 viruses in a highly specific manner thus, can be utilized for the rapid screening of 
virus subtypes.  
Tian et al. reported the ferromagnetic resonance (FMR) based homogeneous and volumetric biosensor for DNA 
detection.[113] This method quantifies the target DNA by measuring the FMR resonance field shift of the 
suspension. The detection strategy for target DNA is based on an isothermal amplification followed by 
hybridizing with detection antibody modified MNPs. In the presence of target DNA strands, antibody-MNP 
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complexes form aggregates and which lowers the net anisotropy as well as increases of the resonance field. For 
the rolling circle amplification (RCA)-based FMR assays, a LOD of 1 pM and linear detection range of 7.8 – 250 
pM are obtained for detecting synthetic Vibrio cholerae target DNA from buffer solutions. For the loop-mediated 
isothermal amplification (LAMP)-based FMR assays, a LOD of 100 aM is obtained for detecting synthetic Zika 
virus target oligonucleotide from 20% serum samples. 
Sun et al. reported a magnetic immunoassay method based on surface enhanced Raman scattering (SERS) 
spectroscopy to detect influenza virus H3N2 (A/Shanghai/4084T/2012) through sandwich-structure complex 
consisting of: SERS tags, target influenza virus and highly SERS-active Fe3O4/Au MNPs as supporting and 
capturing substrates.[114] Using a portable Raman spectrometer, a LOD of 102 TCID50/mL and linear detection 
range of 102 to 5 ×103 TCID50/mL are achieved. 
Barrios-Gumiel et al. reported the carbosilane dendrons decorated MNPs with peripheral carboxyl and 
carboxylate groups for the capture and concentrate of R5-HIV-1NLAD8 and X4-HIV-1NL4.3 strains.[115] The 
carboxyl and carboxylate MNPs assist in achieving rapid and easy diagnostics and reduce/eliminate the risk of 
HIV-1 transmission. 
Wang et al. employed two kinds of labels for the virus antibody and antigen separately.[116] The virus antigens 
were functionalized with fluorescent encoded MNPs, while the antibodies were conjugated to green-emitting 
CdTe quantum dots (QDs). By applying different kinds of fluorescent nanocomposites to the antigens, 
multiplexed detection of equine influenza virus (EIV) and equine infectious anemia virus (EIAV) was achieved 
with a sensitivity of 1.3 ng/mL and 1.2 ng/mL for EIV antigens and EIAV antigens, respectively. 
Zhang et al. synthesized a virus-magnetic-molecularly imprinted polymer (MIP) complex under an applied 
magnetic field.[117] The existence of Fe3O4 MNPs can accelerate the preparation process of the complex. As the 
viruses were captured specifically to the surface of the magnetic-MIP, the size and shape of the particles changed, 
leading to a change in the magnetic resonance light scattering (RLS) signal. The linear concentration range for 
hepatitis A virus was 0.02-1.4 nM, with a detection limit of 6.2 pM. A similar setup was also employed to detect 
the Japanese encephalitis virus (JEV) with a limit of detection of 1.3 pM in human serum.[118] 
Ali et al. employed MNPs in a reverse transcription polymerase chain reaction (RT-PCR) platform for 
multiplexed detection of hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus 
(HIV).[119] Silica coated MNPs were used during nucleic acid extraction. After the RT-PCR process, the viruses 
were then captured by the MNPs coated with amino-modified probes and carboxyl. Multiplexed detection was 
realized with the abilities to detect less than 100 copies of viruses per microliter of serum. 
 
Table 3. Magnetic Materials as Auxiliary Tools in Other Immunoassay Platforms 
Platform Assay Time Pathogens Limit of Detection (LOD) Evaluated Matrices 
Role of magnetic 
materials 
Ref. 
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MALDI-
TOF MS 
1 h H5N2 104.5 – 105.5 TCID50 Virus lysate Magnetic separation [112] 
FMR N.A. 
Vibrio 
cholerae 
1 pM in 1 μL sample PBS 
Magnetic signal source [113] 
Zika virus 100 aM in 1 μL sample 
PBS containing 20% 
fetal bovine serum 
SERS 25 min H3N2 
102 TCID50/mL in 100 μL 
sample 
PBS 
SERS-active magnetic 
supporting substrates 
[114] 
Fluorescent 2 h 
EIV 1.3 ng/mL EIV antigen 
PBS Magnetic separation [116] 
EIAV 1.2 ng/mL EIAV antigen 
RLS 
12 h HAV 6.2 pM N.A. 
Magnetic separation 
and magnetic signal 
source 
[117] 
20 min JEV 1.3 pM Serum 
Magnetic separation 
and magnetic signal 
source 
[118] 
RT-PCR 2 h 
HBV 10 copies in 1 μL sample 
Serum Magnetic separation [119] HCV 10 copies in 1 μL sample 
HIV 100 copies in 1 μL sample 
 
6. Conclusions  
To sum it all up, in the midst of COVID-19 pandemic, the demands for high sensitivity, low cost, rapid, easy-to-
use, and reliable disease testing tools are increasing. Current diagnostic tests for COVID-19 are based on real 
time RT-PCR (rRT-PCR) assays. Although it is sensitive, PCR requires expensive equipment, trained technicians 
to perform the test and have long turnaround times. In addition, its availability is impeded by a shortage in supply 
during the current emergency. As of July 2020, there is no effective vaccine to prevent the spread of COVID-19. 
As the globe is searching for effective cures for COVID-19, actions are also being taken to search for better and 
faster diagnosis tools for timely diagnosis, management, and control the COVID-19. We reviewed the magnetic 
immunoassay literatures prior to COVID-19 and highlighted some promising tools for detecting pathogens as 
well as viruses with high specificity and sensitivity. All the detection platforms reviewed in this paper can be 
extended to other microbial or viral organisms with a change in the specificity of the reagents on MNPs. It is 
expected that the magnetic immunoassay platforms will transform today’s expensive and labor-intensive 
diagnostic techniques into a user-friendly and cost-effective detection protocol with superior or comparable 
sensitivity. This paradigm shift could contribute to better surveillance and control of SARS-CoV-2 infection in 
populations. 
    In addition, this review paper focuses on magnetic immunoassay platforms for pathogen and virus detections 
and different detection tools are reported and categorized by different technologies. However, detection platforms 
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can also be categorized by the target biomarkers such as nucleic acid testing and protein testing (protein antigens 
and antibodies). Other non-magnetic diagnostic tools such as computed tomography (CT) scans and nucleic acid 
analysis are prevalently used for diagnosing and screening COVID-19.[120–124] In the end, however, a very 
basic question still lingers in our mind: where are these nanobiosensors when the world is fighting a global health 
pandemic? Why aren’t they being put to commercialization? This can be answered from several point-of-views. 
From technical view, an ideal biosensor should meet most or all of the following requirements: high sensitivity, 
high selectivity, quick response time, multiplexing capabilities, multiple sensing modes, disposable, long shelf 
life and easy-to-use. Pros and cons for the magnetic biosensors given in Table 2 clearly indicate that all 
technologies lack something or the other from technical point of view. Furthermore, advancements in 
immunoassay platform require investments from industry for the particular technology to be mass manufacturable, 
autonomous and cost-effective. So far, magnetic biosensors have not been commercialized to a very large extent. 
That is why portable magnetic immunoassay platforms haven’t been a big shot in the midst of this global 
pandemic.  
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